Jobs
-
Day 1 of the 2011 IPAC-RS conference featured 13 talks and a panel discussion, covering two topics aligned with the conference theme of “Bring Value to the Patient in a Changing World.” The morning focus,… Read more . . .
-
According to Meda Pharmaceuticals, a Phase 3 trial has shown that its Dymista nasal spray, a combination formulation of azelastine hydrochloride and fluticasone propionate, produced a 40% greater improvement in nasal symptoms than fluticasone alone.… Read more . . .
-
Vectura’s VR496, an inhaled dry powder formulation of heparin sodium, has produced positive results in a Phase 2 study in cystic fibrosis patients, says the company. The product has received orphan drug status from both… Read more . . .
-
Results from the Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) study published in the New England Journal of Medicine show a significant reduction in exacerbations for COPD patients treated with tiotropium compared to those… Read more . . .
-
The FDA has informed Novartis that it needs a three-month extension for its review of data supporting the company’s NDA for QAB149 (indacaterol). The new completion date for the review would be July 2011. The… Read more . . .
-
According to Verona Pharma, the company spent nearly £1 million in 2010 on development of its lead product, RPL554, an inhaled PDE3/4 inhibitor for the treatment of asthma, COPD, and allergic rhinitis. Those R&D costs… Read more . . .
-
The US Supreme Court ruled unanimously that Matrixx Initiatives was wrong when it claimed that it did not have to disclose reports of adverse effects caused by its Zicam nasal spray because the number of… Read more . . .
-
Send workshop and paper proposals by Friday, 29th April 2011. The main theme for the 2012 conference will be sustainability Possible paper and workshop themes may be: new areas of application, materials, surface treatment, shaping,… Read more . . .
-
According to Virginia biotech company Insmed, the US FDA has cleared the company’s Investigational New Drug (IND) application for a Phase 3 trial of its Arikace liposomal amikacin for inhalation in nontuberculous mycobacteria lung infections.… Read more . . .
-
According to reports, Novartis will close its manufacturing facility at Horsham, UK, cutting 550 jobs, but will maintain its respiratory research program at the site. The company employs approximately 330 researchers in the respiratory program.… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA